Bleeding News and Research

RSS

IV ibuprofen effective in reducing fever in hospitalized patients

Cumberland Pharmaceuticals Inc. today announced the publication of data affirming the safety and efficacy of Caldolor (ibuprofen) Injection in treating fever in critically ill and non-critically ill adults. Published in the peer-reviewed journal Critical Care, the study showed that IV ibuprofen was significantly more effective at reducing fever in hospitalized patients than placebo.

8 Oct 2010

VAP bundle helps eliminate hospital-acquired infection

Critically ill patients on a breathing tube are at risk not only from their injuries or diseases, but also from infections they can contract in the hospital. One of the most common infections is pneumonia from breathing tubes. A study of a new multidisciplinary protocol that has all but eliminated such infections at one hospital was reported on today at the 2010 Annual Clinical Congress of the American College of Surgeons.

7 Oct 2010

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA (tranexamic acid) tablets for cyclic heavy menstrual bleeding in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.

7 Oct 2010

Study finds usage of advanced radiology in emergency department increases

From 1998 to 2007, the use of CT or MRI scans in emergency departments for injury-related conditions increased about 3-fold without a similar increase in the prevalence of the diagnosis of certain life-threatening trauma-related conditions, according to a study in the October 6 issue of JAMA.

6 Oct 2010

Cancer cells utilize energy-rich intermediates of sugar metabolism: Research

Cancer research is facing a radical change of direction. Cancer cells do not obtain their energy from the breakdown of sugar to carbon dioxide and water, but from energy-rich intermediates of sugar metabolism instead.

6 Oct 2010

Pre-teen babysitter strengths and weaknesses

Nearly all (98 percent) of 11- to 13-year-old babysitters know who to contact in the event of an intruder or if a child is sick or injured (96 percent) or poisoned (85 percent), according to research presented Sunday, Oct. 3, at the American Academy of Pediatrics (AAP) National Conference and Exhibition in San Francisco. However, 40 percent of younger babysitters reported that they had left children unattended while babysitting, and 20 percent opened the door to strangers.

5 Oct 2010

Octapharma USA launches wilate replacement therapy Web site for von Willebrand Disease

Octapharma USA has launched a comprehensive Web site for wilate® at www.wilateusa.com to provide von Willebrand disease healthcare professionals and patients with easily accessible information, news and updates. The U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate® (von Willebrand Factor/Factor VIII Concentrate, Human), the first replacement therapy developed specifically for von Willebrand Disease (VWD).

5 Oct 2010

Ceremed awarded NIH SBIR grant to develop soluble carrier for topical delivery of antibiotic Vancomycin

Ceremed, Inc. was awarded a Small Business Innovation Research (SBIR) grant, the company's third in a series of grants from the National Institutes of Health to develop a versatile soluble carrier with bone hemostatic properties for targeted delivery of therapeutic agents directly to surgical sites. The recently awarded grant will aid Ceremed in its effort to develop a soluble carrier to topically deliver the antibiotic Vancomycin.

5 Oct 2010

CWRU researcher receives New Innovator Award to advance synthetic platelet technology

A Case Western Reserve University researcher will receive a $2.3 million New Innovator Award today to further develop and broaden the uses of synthetic platelets and the technology that makes them work.

4 Oct 2010

Physical activity reduces risk for womb cancer

Women who exercise and keep active are around 30 per cent less likely to develop womb cancer than couch potatoes - according to a new study published in the British Journal of Cancer today.

30 Sep 2010

Study shows Artelon scaffold improves cartilage repair outcome

A laboratory study (in vitro) and an animal study, which are currently being presented at the 9th World Congress of the International Cartilage Repair Society, demonstrate that Artelon functions as a scaffold for cells in conjunction with cartilage repair.

29 Sep 2010

Intrauterine devices for treatment of endometrial cancer

Intrauterine devices, originally developed as contraceptives, can also be used to treat and cure cancer of the endometrium according to new research published online in the cancer journal, Annals of Oncology today (Wednesday 29 September). The finding opens the way for young women with the disease, which affects the lining of the womb, to be treated without the need for a hysterectomy, thus preserving their fertility until they have had all the children they want.

29 Sep 2010

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.

27 Sep 2010

Double-Balloon Enteroscopy shows potential benefits in children

The use of device assisted enteroscopy, a technique that allows complete examination of the small bowel, may be just as successful pediatrics as it has been in adult medicine, according to a study from Nationwide Children's Hospital.

27 Sep 2010

Entellus Medical announces Clinic versus OR study results for chronic sinusitis

Entellus Medical, a Minnesota based medical technology company, shared the results of a 12-month study entitled "Clinic versus OR A Comparative Analysis of Ostial Dilation for CRS," presented on September 25th during the 56th annual meeting of the American Rhinologic Society in Boston, Mass.

27 Sep 2010

FDA approves Beyaz tablets to increase folate level in women

The U.S. Food and Drug Administration today approved Beyaz tablets, an estrogen/progestin combined oral contraceptive that also contains a folate (levomefolate calcium 0.451 mg).

27 Sep 2010

ENTrigue announces first clinical experience with Ventera sinus dilation systems

ENTrigue Surgical, Inc., a San Antonio, Texas-based company that designs, develops, manufactures and distributes medical devices used for Ear, Nose and Throat surgical procedures, announced today the first clinical experience with its Ventera sinus dilation systems.

23 Sep 2010

ENTrigue partners with HemCon to distribute hemostatic surgical gel

HemCon Medical Technologies, a global innovative developer of advanced medical technologies and products, has recently partnered with ENTrigue Surgical, Inc., a leading provider of medical devices and therapies for surgeries of the Ear, Nose and Throat, to develop and distribute HemCon's latest breakthrough product, a hemostatic surgical gel.

23 Sep 2010

Implantation of new bioprosthetic-tissue valve in patients with severe aortic stenosis saves lives

Implantation of a new bioprosthetic-tissue valve into the hearts of patients who have severe aortic stenosis and are too sick or too old for open-heart surgery has been found to both save lives and improve the quality of those lives, according to a new multicenter study, to be published online at 2 p.m. Pacific time today in the New England Journal of Medicine.

23 Sep 2010

Hyponatremia may lead to neurological complications

A new study published in the October issue of the journal Hepatology found that patients with severe portal-hypertensive bleeding who are treated with terlipressin may experience an acute reduction of sodium in their blood. This reduction in serum sodium, known as hyponatremia, can cause adverse reactions such as neurological complications, and is rapidly reversible upon terlipressin withdrawal.

23 Sep 2010